alendronate has been researched along with Weight Gain in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 7.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "In an effort to elucidate the effect of high-frequency (HF) loading on bone and to optimize its potential for treatment osteoporosis, this study aimed to investigate the effect of HF loading via whole body vibration (WBV), alone or in association with bisphosphonate treatment (alendronate--ALN), on the micro-architecture of ovariectomy (OVX)-induced compromised bone." | 3.81 | Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats. ( Camargos, GV; Chatterjee, M; Duyck, J; Faot, F; Hatori, K; Sasaki, K; Vandamme, K, 2015) |
| "We report a direct comparison of receptor activator of nuclear factor kappa B ligand (RANKL) inhibition (RANK-Fc) with bisphosphonate treatment (alendronate, ALN) from infancy through early adulthood in a mouse model of osteogenesis imperfecta." | 3.78 | Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta. ( Bargman, R; Boskey, AL; DiCarlo, E; Pleshko, N; Posham, R; Raggio, C, 2012) |
| "Alendronate is an aminobisphosphonate that inhibits bone resorption in osteoporotic humans and rats but does not induce osteomalacia." | 1.31 | Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat. ( Emanuele, MA; Lapaglia, N; Moskal, SF; Steiner, J; Wezeman, FH, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatori, K | 1 |
| Camargos, GV | 1 |
| Chatterjee, M | 1 |
| Faot, F | 1 |
| Sasaki, K | 1 |
| Duyck, J | 1 |
| Vandamme, K | 1 |
| Plotkin, LI | 1 |
| Lezcano, V | 1 |
| Thostenson, J | 1 |
| Weinstein, RS | 1 |
| Manolagas, SC | 1 |
| Bellido, T | 1 |
| Bargman, R | 1 |
| Posham, R | 1 |
| Boskey, AL | 1 |
| DiCarlo, E | 1 |
| Raggio, C | 1 |
| Pleshko, N | 1 |
| Conte Neto, N | 1 |
| Spolidorio, LC | 1 |
| Andrade, CR | 1 |
| S Bastos, A | 1 |
| Guimarães, M | 1 |
| Marcantonio, E | 1 |
| Liu, ZP | 1 |
| Li, WX | 1 |
| Yu, B | 1 |
| Huang, J | 1 |
| Sun, J | 1 |
| Huo, JS | 1 |
| Liu, CX | 1 |
| Wezeman, FH | 1 |
| Emanuele, MA | 1 |
| Moskal, SF | 1 |
| Steiner, J | 1 |
| Lapaglia, N | 1 |
6 other studies available for alendronate and Weight Gain
| Article | Year |
|---|---|
Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Combined Modality Therapy; Female; Hormones; | 2015 |
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.
Topics: Alendronate; Animals; Apoptosis; Bone Density; Bone Resorption; Cell Differentiation; Cells, Culture | 2008 |
Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Topics: Acid Phosphatase; Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conserva | 2012 |
Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents.
Topics: Alendronate; Alkaline Phosphatase; Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of t | 2013 |
Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model.
Topics: Absorptiometry, Photon; Alendronate; Analysis of Variance; Animals; Bone and Bones; Bone Density; Ca | 2005 |
Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat.
Topics: Alcoholism; Alendronate; Alkaline Phosphatase; Animals; Biomechanical Phenomena; Bone and Bones; Bon | 2000 |